Antimicrobial Peptides as Antibiotic Adjuvants: Overcoming Resistance through Multifaceted Mechanisms
Authors:
- 11 June 2026
- journal article
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
Abstract
Antimicrobial resistance (AMR) has escalated into a major global health crisis, demanding alternative strategies beyond the discovery of new antibiotics. Antimicrobial peptides (AMPs) represent a promising class of adjuvant therapeutics capable of restoring or enhancing the activity of conventional antibiotics. Owing to their structural diversity and multifunctional mechanisms, AMPs can potentiate antibiotic efficacy through membrane permeabilization, disruption of biofilm architecture, inhibition of efflux pumps and β-lactamases, modulation of quorum sensing, and immune regulation. Recent advances show that rationally engineered peptides, synthetic derivatives, peptide hybrids, and transmembrane mimetic strategies can overcome both intrinsic and acquired resistance phenotypes across clinically relevant Gram-negative and Gram-positive pathogens. Furthermore, peptide adjuvants enable dose reductions of toxic antibiotics and can circumvent pathogen persistence, thereby improving both pharmacodynamic outcomes and therapeutic index. Nevertheless, major translational bottlenecks remain, including peptide instability, proteolytic susceptibility, toxicity, and limited in vivo validation. Peptide engineering, incorporation of D-residues, cyclization, conjugation with antibiotics, and advanced delivery systems such as nanoparticles and liposomal platforms are increasingly addressing these limitations. Collectively, this review highlights the therapeutic potential of peptide-antibiotic combinations as next-generation adjuvant therapies and emphasizes the need for integrative computational, chemical, mechanistic, and in vivo approaches to accelerate their clinical development.Keywords
Funding Information
- Cochin University of Science and Technology (U-PDF)
- CSIR-JRF
This publication has 139 references indexed in Scilit:
- The broad‐spectrum antimicrobial peptide BMAP‐27B potentiates carbapenems against NDM‐producing pathogens in food animalsmLife, 2025
- Non‐Membrane Active Peptide Resensitizes MRSA to β‐Lactam Antibiotics and Inhibits S. aureus VirulenceAdvanced Science, 2025
- Short Synthetic Peptides as Efflux Pump Inhibitors Resensitising Multidrug-Resistant Escherichia coli TG1 and Erwinia amylovora 1189 bacteriaInternational Journal of Peptide Research and Therapeutics, 2024
- Toward a broad‐spectrum peptide‐based inhibitor of small multidrug resistance efflux pumpsPeptide Science, 2023
- Antimicrobial Peptide Synergies for Fighting Infectious DiseasesAdvanced Science, 2023
- A Glycosylated Cationic Block Poly(β‐peptide) Reverses Intrinsic Antibiotic Resistance in All ESKAPE Gram‐Negative BacteriaAngewandte Chemie International Edition, 2020
- Antimicrobial Peptides in Cutaneous Wound Healing2015
- Peptide IDR‐1018: modulating the immune system and targeting bacterial biofilms to treat antibiotic‐resistant bacterial infectionsJournal of Peptide Science, 2014
- Human β‐defensin 3 affects the activity of pro‐inflammatory pathways associated with MyD88 and TRIFEuropean Journal of Immunology, 2011
- Synergy assessed by checkerboard a critical analysisDiagnostic Microbiology and Infectious Disease, 1993